Long‐term efficacy and safety of porcine islet macrobeads in nonimmunosuppressed diabetic cynomolgus macaques. (6th April 2022)

• Record Type: Journal Article
• Authors: Holdcraft, Robert W.; Graham, Melanie J.; Bemrose, Melissa A.; Mutch, Lucas A.; Martis, Prithy C.; Janecek, Jody L.; Hall, Richard D.; Smith, Barry H.; Gazda, Lawrence S.
• Is Part Of: Xenotransplantation. Volume 29:Number 3(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-06
• Subjects: diabetes -- encapsulation -- porcine islets -- xenotransplantation; Xenografts -- Periodicals; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/xen.12747
• Languages: English
• ISSNs: 0908-665X

Abstract

Abstract: Although human islet transplantation has proven to provide clinical benefits, especially the near complete amelioration of hypoglycemia, the supply of human islets is limited and insufficient to meet the needs of all people that could benefit from islet transplantation. Porcine islets, secreting insulin nearly identical to that of human insulin, have been proposed as a viable supply of unlimited islets. Further, encapsulation of the porcine islets has been shown to reduce or eliminate the use of immunosuppressive therapy that would be required to prevent rejection of the foreign islet tissue. The goal of the current study was to determine the long‐term safety and efficacy of agarose encapsulated porcine islets (macrobeads) in diabetic cynomolgus macaques, in a study emulating a proposed IND trial in which daily exogenous insulin therapy would be reduced by 50% with no loss of glucose regulation. Four of six animals implanted with macrobeads demonstrated ≥ 30% reduction in insulin requirements in year 1 of follow‐up. Animals were followed for 2, 3.5, and 7.4 years with no serious adverse events, mortality or evidence of pathogen transmission. This study supports the continued pursuit of encapsulated porcine islet therapy as a promising treatment option for diabetes mellitus.